Verified· 3 sources

Vandria SA

Summary

About the company

Vandria SA is a clinical-stage biotech company developing first-in-class small molecules against a novel metabolic target to restore mitochondrial function and reduce chronic inflammation for the treatment of age-related and chronic diseases. Its lead clinical CNS asset, VNA-318, is an orally available, brain-penetrant small molecule that completed Phase I studies demonstrating safety, tolerability and a pharmacokinetic profile suitable for once-daily oral dosing.

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Vandria SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Vandria SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Mentions & media

No knowledge articles yet

Vandria SA in comparison

Industry comparisons are coming soon

Similar companies